[Cost-benefit aspects of taxane therapy]

Pharm Unserer Zeit. 2005;34(2):138-47. doi: 10.1002/pauz.200400114.
[Article in German]
No abstract available

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents, Phytogenic / adverse effects
  • Antineoplastic Agents, Phytogenic / economics*
  • Antineoplastic Agents, Phytogenic / therapeutic use*
  • Docetaxel
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / economics*
  • Neoplasms / psychology
  • Quality of Life
  • Taxoids / adverse effects
  • Taxoids / economics*
  • Taxoids / therapeutic use*

Substances

  • Antineoplastic Agents, Phytogenic
  • Taxoids
  • Docetaxel